SCHEMBL4548446

SCHEMBL4548446

COc1ccc(-n2cnc(CCC(=O)O)n2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 2/20 0.48
RXRA P19793 1/20 0.46
RXRB P28702 1/20 0.46
RXRG P48443 1/20 0.46
ALDH1A1 P00352 6/20 0.46
MAPT P10636 6/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PTGS2 P35354 2/20 0.46
GAA P10253 3/20 0.45
KDM4E B2RXH2 4/20 0.44
PKM P14618 2/20 0.44
PTGS1 P23219 1/20 0.43
POLB P06746 3/20 0.43
LMNA P02545 3/20 0.42
ATM Q13315 1/20 0.42
TP53 P04637 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HPGD P15428 2/20 0.41
ALOX15 P16050 2/20 0.41
CASP1 P29466 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4548448 0.88 CYP11B1 (0.50) ALDH1A1MAPTPTGS2GAAPKM
SCHEMBL4548454 0.83 MAPT (0.39) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL10719947 0.80 MAPT (0.48) FFAR1RXRARXRBRXRGALDH1A1
SCHEMBL4548444 0.80 P2RX7 (0.51) ALDH1A1MAPTPTGS2KDM4EPKM
SCHEMBL7501503 0.77 RXRA (0.53) FFAR1RXRARXRBRXRGALDH1A1
SCHEMBL31301332 0.76 MAPT (0.55) ALDH1A1MAPTL3MBTL1PTGS2PKM
SCHEMBL11605238 0.74 RXRA (0.44) FFAR1RXRARXRBRXRG
SCHEMBL11605245 0.73 RXRA (0.50) FFAR1RXRARXRBRXRGALDH1A1
SCHEMBL28300140 0.72 LTA4H (0.51) ALDH1A1MAPTKDM4EPOLBTP53
SCHEMBL4548449 0.71 NOTUM (0.64) ALDH1A1MAPTL3MBTL1GAAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178750-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. (US) 2012-07-12 US disclosed
US-20120178750-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. (US) 2012-07-12 US disclosed
US-8168649-B2 Niacin receptor agonists, compositions containing such compounds and methods of treatment Merk Sharp & Dohme Corp. (US) 2012-05-01 US disclosed
US-8168649-B2 Niacin receptor agonists, compositions containing such compounds and methods of treatment Merk Sharp & Dohme Corp. (US) 2012-05-01 US disclosed
US-20100144778-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME LLC 2010-06-10 US disclosed
US-20100144778-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME LLC 2010-06-10 US disclosed
WO-2007002557-A1 NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK & CO., INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144778-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment HCAR1, HCAR2, GPR119 FFAR1 4/4885RXRA 95/4885RXRB 100/4885
US-20120178750-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment HCAR1, HCAR2, FFAR1 FFAR1 3/4885RXRA 104/4885RXRB 118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.